| Autor: |
Afani S, Alejandro, Orellana R, Laura, Duarte J, Paula, Acevedo M, William, Morales B, Ornar, Wolff R, Marcelo, Vásquez, Patricia, Beltrán, Carlos |
| Jazyk: |
Spanish; Castilian |
| Rok vydání: |
2007 |
| Předmět: |
|
| Zdroj: |
Revista médica de Chile, Volume: 135, Issue: 10, Pages: 1237-1244, Published: OCT 2007 |
| Popis: |
Background: Resistance limits the effectiveness of anti-retroviral therapy. In Chile, there is free access to highly active anti-retroviral therapy since 2001, but there is no information about the frequency of mutations associated to drug resistance. Aim: To determine the most common mutations associated to anti-retroviral drug resistance in Chile. Materials and Methods: Retrospective study of 710 genotype analysis coming from 568 patients aged 22 to 70 years (85% males) with virological failure. The analysis was performed using a commercially available sequencing kit (Trugene HIV-1 genotypic assay from Bayer S.A). Results: Mean CD4+ cell count and viral load were 154 cells/fil and 228784 RNA copies/ml, respectively. The frequency of resistance to nucleoside RT inhibitors (NRTI), non nucleoside RT inhibitors (NNRTI) and protease inhibitors (PI) was 71 %, 62% and 22%, respectively. The most common mutations found were T215Y (46%), L10F (44%), Ml84V (3896), K103N (35%) and M41L (32%). Fifty five percent of mutations corresponded to the TAM (thymidine analogue mutations) group. Multiresistance was 47% to NNRTI, 7% to NRTI, 4% to PI and 0.7% to all groups. During the four years of the study, there was a significant increase in NNRTI resistance. Conclusions: These data provides important information about the epidemiology of drug resistance mutations and should help to design newHAARTstrategies |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
